āshibio Secures $40M to Pave the Way for Breakthrough Therapies in Bone and Connective Tissue Disorders
In a significant stride towards advancing treatments for severe bone and connective tissue disorders, āshibio emerges from stealth mode with a remarkable $40 million infusion from its Seed and Series A financing rounds. Spearheaded by MPM BioImpact and bolstered by investments from Agent Capital, YK Bioventures, and Mirae Asset Venture Investment, this funding positions āshibio…